Citations

Showing 10 of 108152 citations.

NCCN Guidelines Insights: Survivorship, Version 2.2019
Sanft, Tara , Denlinger, Crystal S. , Demark‐Wahnefried, Wendy , Goldman, Mindy, Khakpour, Nazanin , Koura, Divya, Langbaum, Terry S., McDonough, Allison L. , Melisko, Michelle , Mooney, Kathi , Moslehi, Javid J. , O’Connor, Tracey L. , Overholser, Linda , Peterson, Lindsay L. , Pirl, William F. , Rodriguez, Maria Alma , Ruddy, Kathryn J. , Smith, Sophia K. , Syrjala, Karen L. , Urba, Susan G., Zee, Phyllis C. , McMillian, Nicole R., Freedman-Cass, Deborah A., Broderick, Gregory, Demark-Wahnefried, Wendy , Armenian, Saro H. , Baker, Kevin Scott , Broderick, Gregory A. , Friedman, Debra L. , Hudson, Melissa M. , Lally, Robin Mary , Moore, Halle C. F. , Paskett, Electra D. , Tevaarwerk, Amyé

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 18, 2019 | Volume: 17 | Issue: 7 | Pages: 784-794

10.6004/jnccn.2019.0034 | PMID 31319383 Get It

The NCCN Guidelines for Survivorship provide screening, evaluation, and treatment recommendations for consequences of cancer and cancer treatment to aid healthcare professionals who work with survivors of adult-onset cancer. Guidance is also provided to help promote physical activity, weight management, and proper immunizations in survivors and to facilitate care coordination to ensure that all needs are addressed. These NCCN Insights summarize some of the topics discussed by the NCCN Survivorship Panel during the 2019 update of the guidelines, including the survivorship population addressed, ways to improve care coordination, and pain management.
Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Ajani, Jaffer A. , D’Amico, Thomas A., Bentrem, David J., Corvera, Carlos U. , Das, Prajnan , Denlinger, Crystal S. , Enzinger, Peter C. , Fanta, Paul T. , Farjah, Farhood , Gerdes, Hans, Glasgow, Robert E. , Hayman, James A. , Hochwald, Steven N. , Hofstetter, Wayne L. , Ilson, David H. , Jaroszewski, Dawn E. , Johung, Kimberly L. , Keswani, Rajesh N. , Kleinberg, Lawrence , Leong, Stephen , Ly, Quan P. , Matkowskyj, Kristina A. , McNamara, Michael J. , Mulcahy, Mary F. , Paluri, Ravi Kumar , Park, Haeseong , Poultsides, George A. , Roses, Robert E. , Strong, Vivian E. , Wiesner, Georgia L. , Willett, Christopher G. , Wright, Cameron D., McMillian, Nicole R., Pluchino, Lenora A. , Jaroszewski, Dawn, Ajani, Jaffer A , Bentrem, David J. , Chao, Joseph , Gibson, Michael K. , Perry, Kyle A. , Pimiento, José M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 18, 2019 | Volume: 17 | Issue: 7 | Pages: 855-883

10.6004/jnccn.2019.0033 | PMID 31319389 Get It

Abstract Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide. Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and adenocarcinoma is most common in North America and Western Europe. Surgery is a major component of treatment of locally advanced resectable esophageal and esophagogastric junction (EGJ) cancer, and randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival. Targeted therapies including trastuzumab, ramucirumab, and pembrolizumab have produced encouraging results in the treatment of patients with advanced or metastatic disease. Multidisciplinary team management is essential for all patients with esophageal and EGJ cancers. This selection from the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers focuses on recommendations for the management of locally advanced and metastatic adenocarcinoma of the esophagus and EGJ.
Role of BNP vs NT-proBNP Testing in the Age of New Drug Therapies: Sacubitril-Valsartan
Apple, Fred S. , Daniels, Lori B. , Omland, Torbjørn , Ordóñez‐Llanos, Jordi , Jaffe, Allan S. , Jaffe, Allan, Daniels, Lori B , Januzzi, James Louis , Jaffe, Allan S.

Mayo Clinic

Clinical Chemistry | July 18, 2019 | Volume: 65 | Issue: 9 | Pages: 1076-1083

10.1373/clinchem.2018.289371 | PMID 31320381 Get It

Short‐term safety and long‐term benefits of stent postdilation after primary percutaneous coronary intervention: Results of a cohort study
Saadat, Nasser, Saadatagah, Seyedmohammad , Nargesi, Arash Aghajani , Alidoosti, Mohammad , Poorhosseini, Hamidreza , Amirzadegan, Alireza , Ghodsi, Saeed , Salarifar, Mojtaba , Aghajani Nargesi, Arash, Ghodsi, Saeed , Lashkari, Reza, Mortazavi, Seyedeh Hamideh , Jalali, Arash

Mayo Clinic

Catheterization and Cardiovascular Interventions | July 18, 2019 | Volume: 95 | Issue: 7 | Pages: 1249-1256

10.1002/ccd.28396 | PMID 31318488 Get It

AbstractAimAchieving the optimal apposition of coronary stents during percutaneous coronary intervention is not always feasible. The risks and benefits of stent postdilation in primary percutaneous coronary intervention (PPCI) in patients with ST‐elevation myocardial infarction (STEMI) have remained controversial. We sought to evaluate the immediate angiographic and long‐term outcomes in patients with and without stent postdilation.MethodsA cohort of patients (n = 1,224) with STEMI, treated with PPCI (n = 500 postdilated; n = 724 controls), were studied. The flow grade, the myocardial blush grade, and the frame count were considered angiographic outcomes. The clinical outcomes were major adverse cardiovascular events (MACE)—comprising cardiac death, nonfatal MI, and repeat revascularization—and the device‐oriented composite endpoint (DOCE)—consisting of cardiac death, target lesion revascularization, and target vessel revascularization.ResultsThe flow and myocardial blush grades were not different between the two groups, and the frame count was significantly lower in the postdilation group (15.7 ± 8.4 vs. 17 ± 10.4; p < .05). The patients were followed up for 348 ± 399 days. DOCE (2.2% vs. 5.8%) and cardiac mortality (1.2% vs. 3.2%) were lower in the postdilation group. In the fully adjusted propensity score‐matched analysis, postdilation was associated with decreased DOCE (HR = 0.40 [0.18–0.87], p = .021).ConclusionsSelective postdilation improved some angiographic and clinical outcomes and could not be discouraged in PPCI on patients with STEMI.
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE
Perez, Edith A. , Barrios, Carlos H. , Eiermann, W., Im, Young‐Hyuck , Conte, PierFranco , Pieńkowski, Tadeusz , Burris, Howard A. , Petersen, Jennifer, Haas, Sanne de , Hoersch, Silke, Patre, Monika, Ellis, Paul Anthony, Conte, Pierfranco , Toi, Masakazu , Martín, Miguel , Pivot, Xavier B. , Petersen, Jennifer A.

Mayo Clinic

Cancer | July 18, 2019 | Volume: 125 | Issue: 22 | Pages: 3974-3984

10.1002/cncr.32392 | PMID 31318460 Get It

Background In the phase 3 MARIANNE trial, trastuzumab emtansine (T‐DM1) with or without pertuzumab showed noninferior progression‐free survival and better tolerability than trastuzumab plus a taxane (HT) for the first‐line treatment of human epidermal growth factor receptor 2 (HER2)–positive advanced breast cancer. This article reports the final descriptive overall survival (OS) analysis, updated safety data, and additional patient‐reported outcomes and biomarker analyses. Methods OS was assessed in 1095 patients with HER2‐positive breast cancer and no prior therapy for advanced disease who had been randomized to HT, T‐DM1 plus a placebo (hereafter T‐DM1), or T‐DM1 plus pertuzumab (T‐DM1+pertuzumab). A post hoc exploratory landmark analysis of OS, baseline patient and disease characteristics, and tumor biomarkers in patients with and without an objective tumor response (OR) according to the Response Evaluation Criteria in Solid Tumors within 6.5 months of randomization was conducted. Results The median OS was similar across groups (50.9, 53.7, and 51.8 months for the HT, T‐DM1, and T‐DM1+pertuzumab groups, respectively). Among patients with an OR, the median OS was longer with T‐DM1 (64.4 months) and T‐DM1+pertuzumab (not reached) versus HT (56.3 months). No baseline characteristics or biomarkers were strongly associated with OR. The incidence of grade 3 or higher adverse events was greater with HT (55.8%) than T‐DM1 (47.1%) or T‐DM1+pertuzumab (48.6%). The median time to clinically meaningful deterioration (a 3‐point or greater change) in neurotoxicity symptoms was shorter with HT (2.1 months) and T‐DM1+pertuzumab (4.2 months) than T‐DM1 (6.2 months). Fewer patients reported alopecia and diarrhea and were bothered by treatment side effects in the T‐DM1 arm. Conclusions These results support T‐DM1 as a first‐line treatment for patients with HER2‐positive metastatic breast cancer who are deemed unsuitable for taxane‐based therapy.
Utilization of Palliative Care for Cardiogenic Shock Complicating Acute Myocardial Infarction: A 15‐Year National Perspective on Trends, Disparities, Predictors, and Outcomes
Vallabhajosyula, Saraschandra , Prasad, Abhiram , Murphree, Dennis H. , Ingram, Cory , Mueller, Paul S. , Holmes, David R. , Barsness, Gregory W. , Dunlay, Shannon M. , Vallabhajosyula, Saraschandra , Prasad, Abhiram , Gersh, Bernard J.

Mayo Clinic

Journal of the American Heart Association | July 18, 2019 | Volume: 8 | Issue: 15 | Pages: No page available

10.1161/jaha.119.011954 | PMID 31315497 Get It

Background This study sought to evaluate the 15‐year national utilization, trends, predictors, disparities, and outcomes of palliative care services ( PCS ) use in cardiogenic shock complicating acute myocardial infarction. Methods and Results A retrospective cohort from January 1, 2000 through December 31, 2014 was analyzed using the National Inpatient Sample database. Administrative codes for acute myocardial infarction–cardiogenic shock and PCS were used to identify eligible admissions. The primary outcomes were the frequency, utilization trends, and predictors of PCS . Secondary outcomes included in‐hospital mortality and resources utilization. Multivariable regression and propensity‐matching analyses were used to control for confounding. In this 15‐year period, there were 444 253 acute myocardial infarction–cardiogenic shock admissions, of which 4.5% received PCS . The cohort receiving PCS was older, of white race, female sex, and with higher comorbidity and acute organ failure. The PCS cohort received fewer cardiac procedures, but more noncardiac organ support therapies. Older age, female sex, white race, higher comorbidity, higher socioeconomic status, admission to a larger hospital, and admission after 2008 were independent predictors of PCS use. Use of PCS was independently associated with higher in‐hospital mortality (odds ratio 6.59 [95% CI 6.37–6.83]; P <0.001). The cohort with PCS use had >2‐fold higher in‐hospital mortality, 12‐fold higher use of do‐not‐resuscitate status, lesser in‐hospital resource utilization, and fewer discharges to home. Similar findings were observed in the propensity‐matched cohort. Conclusions PCS use in patients with acute myocardial infarction–cardiogenic shock is low, though there is a trend towards increased adoption. There are significant patient and hospital‐specific disparities in the utilization of PCS .
Racial Disparities in the Utilization and Outcomes of Structural Heart Disease Interventions in the United States
Holmes, David R. , Berzingi, Chalak , Alkhouli, Mohamad , Alqahtani, Fahad

Mayo Clinic

Journal of the American Heart Association | July 18, 2019 | Volume: 8 | Issue: 15 | Pages: No page available

10.1161/jaha.119.012125 | PMID 31315490 Get It

Background Data on race‐ and ethnicity‐based disparities in the utilization and outcomes of structural heart disease interventions in the United States are scarce. Methods and Results We used the National Inpatient Sample (2011‐2016) to examine racial and ethnic differences in the utilization, in‐hospital outcomes, and cost of structural heart disease interventions among patients ≥65 years of age. A total of 106 119 weighted hospitalizations for transcatheter aortic valve replacement, transcatheter mitral valve repair, and left atrial appendage occlusion were included. The utilization rates (defined as the number of procedures performed per 100 000 US people >65 years of age) were higher in whites compared with blacks and Hispanics for transcatheter aortic valve replacement (43.1 versus 18.0 versus 21.1), transcatheter mitral valve repair (5.0 versus 3.2 versus 3.2), and left atrial appendage occlusion (6.6 versus 2.1 versus 3.5), respectively ( P <0.001). Black and Hispanic patients had distinctive socioeconomic and clinical risk profiles compared with white patients. There were no significant differences in the adjusted in‐hospital mortality or key complications between patients of white race, black race, and Hispanic ethnicity following transcatheter aortic valve replacement, transcatheter mitral valve repair, or left atrial appendage occlusion. No difference in cost was observed between white and black patients following any of the 3 procedures. However, Hispanic patients incurred modestly higher cost with transcatheter mitral valve repair and left atrial appendage occlusion compared with white patients. Conclusions Racial and ethnic disparities exist in the utilization of structural heart disease interventions in the United States. Nonetheless, adjusted in‐hospital outcomes were comparable among white, black, and Hispanic patients. Further studies are needed to understand the reasons for these utilization disparities.
What’s New in Musculoskeletal Infection
Fehring, Thomas K. , Fehring, Keith A. , Hewlett, Angela , Higuera, Carlos A. , Otero, Jesse E. , Tande, Aaron J. , Tande, Aaron , Higuera, Carlos

Mayo Clinic

Journal of Bone and Joint Surgery | July 18, 2019 | Volume: 101 | Issue: 14 | Pages: 1237-1244

10.2106/jbjs.19.00403 | PMID 31318802 Get It

Definition of Successful Infection Management and Guidelines for Reporting of Outcomes After Surgical Treatment of Periprosthetic Joint Infection
Fillingham, Yale A. , Valle, Craig J. Della , Suleiman, Linda I. , Springer, Bryan D. , Gehrke, Thorsten , Bini, Stefano A. , Segreti, John , Chen, Antonia F. , Goswami, Karan , Tan, Timothy L. , Shohat, Noam , Díaz-Ledezma, Claudio , Schwartz, Adam J. , Gehrke, Thorsten A. , Parvizi, Javad , Chen, Antonia F

Mayo Clinic

Journal of Bone and Joint Surgery | July 18, 2019 | Volume: 101 | Issue: 14 | Pages: e69

10.2106/jbjs.19.00062 | PMID 31318814 Get It

Acquired Idiopathic Stiffness After Total Knee Arthroplasty
Tibbo, Meagan E. , Limberg, Afton K. , Salib, Christopher G. , Ahmed, Ahmed T. , Wijnen, André J. van , Berry, Daniel M. , Abdel, Matthew P. , Berry, Daniel J. , van Wijnen, Andre J , Abdel, Matthew P , Berry, Daniel J , Berry, Daniel J.

Mayo Clinic

Journal of Bone and Joint Surgery | July 18, 2019 | Volume: 101 | Issue: 14 | Pages: 1320-1330

10.2106/jbjs.18.01217 | PMID 31318813 Get It

Background: Stiffness is a common reason for suboptimal clinical outcomes after primary total knee arthroplasty (pTKA). There is a lack of consensus regarding its definition, which is often conflated with its histopathologic subcategory—i.e., arthrofibrosis. There is value in refining the definition of acquired idiopathic stiffness in an effort to select for patients with arthrofibrosis. We conducted a systematic review and meta-analysis to establish a consensus definition of acquired idiopathic stiffness, determine its prevalence after pTKA, and identify potential risk factors for its development. Methods: MEDLINE, Embase, Cochrane Controlled Register of Trials (CENTRAL), and Scopus databases were searched from 2002 to 2017. Studies that included patients with stiffness after pTKA were screened with strict inclusion and exclusion criteria to isolate the subset of patients with acquired idiopathic stiffness unrelated to known extrinsic or surgical causes. Three authors independently assessed study eligibility and risk of bias and collected data. Outcomes of interest were then analyzed according to age, sex, and body mass index (BMI). Results: In the 35 included studies (48,873 pTKAs), the mean patient age was 66 years. In 63% of the studies, stiffness was defined as a range of motion of <90° or a flexion contracture of >5° at 6 to 12 weeks postoperatively. The prevalence of acquired idiopathic stiffness after pTKA was 4%, and this did not differ according to age (4%, I 2 = 95%, among patients <65 years old and 5%, I 2 = 96%, among those ≥65 years old; p = 0.238). The prevalence of acquired idiopathic stiffness was significantly lower in males (1%, I 2 = 85%) than females (3%, I 2 = 95%) (p < 0.0001) as well as in patients with a BMI of <30 kg/m 2 (2%, I 2 = 94%) compared with those with a BMI of ≥30 kg/m 2 (5%, I 2 = 97%) (p = 0.027). Conclusions: Contemporary literature supports the following definition for acquired idiopathic stiffness: a range of motion of <90° persisting for >12 weeks after pTKA in patients in the absence of complicating factors including preexisting stiffness. The mean prevalence of acquired idiopathic stiffness after pTKA was 4%; females and obese patients were at increased risk. Level of Evidence: Therapeutic Level IV . See Instructions for Authors for a complete description of levels of evidence.